{'fraction_non_alphanumeric': 0.013089005235602094, 'fraction_numerical': 0.0, 'mean_word_length': 5.707602339181286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The escalating role of epidermal growth factor receptor inhibitors in cancer management: clinical considerations for the health system pharmacist.

Disclaimer: The clinical information presented in this manuscript is as current as possible at the time of manuscript preparation. Owing to regularly emerging data on developmental or newly approved drug therapies, this manuscript includes information published or presented in abstract form and available to the authors up until the time of manuscript submission. Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. 
 
The information presented in this activity is meant to inform and not to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers of use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.